Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Patients with type 2 diabetes (T2DM) often have multiple comorbidities which may impact the selection of antihyperglycemic therapies. The purpose of this study was to quantify the prevalence and co-prevalence of common comorbidities. RESEARCH DESIGN AND METHODS: A retrospective study was conducted using the Quintiles Electronic Medical Record database. Adult patients with T2DM who had ≥1 encounter from July 2014 to June 2015 (index period) with ≥1 year medical history available were included. The index date was defined as the most recent encounter date during the 1 year index period. MAIN OUTCOME MEASURES: Comorbid conditions were assessed using all data available prior to and including the index date. Patient characteristics, laboratory measures, and comorbidities were summarized via descriptive analyses, overall and by subgroups of age (<65, 65-74, 75+ years) and gender. RESULTS: Of the 1,389,016 eligible patients, 53% were female and the median age was 65 years. 97.5% of patients had at least one comorbid condition in addition to T2DM and 88.5% had at least two. The comorbidity burden tended to increase in older age groups and was higher in men than women. The most common conditions in patients with T2DM included hypertension (HTN) in 82.1%; overweight/obesity in 78.2%; hyperlipidemia in 77.2%; chronic kidney disease (CKD) in 24.1%; and cardiovascular disease (CVD) in 21.6%. The highest co-prevalence was demonstrated for the combination of HTN and hyperlipidemia (67.5%), followed by overweight/obesity and HTN (66.0%), overweight/obesity and hyperlipidemia (62.5%), HTN and CKD (22.4%), hyperlipidemia and CKD (21.1%), HTN and CVD (20.2%), hyperlipidemia and CVD (20.1%), overweight/obesity and CKD (19.1%) and overweight/obesity and CVD (17.0%). LIMITATIONS: Limitations include the potential for misclassification/underreporting due to the use of diagnostic codes, drug codes, or laboratory measures for identification of medical conditions. CONCLUSIONS: The vast majority of patients with T2DM have multiple comorbidities. To ensure a comprehensive approach to patient management, the presence of multimorbidity should be considered in the context of clinical decision making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The links between obesity and T2DM are well recognised, particularly the effects of excess visceral adipose tissue and disturbances of lipid metabolism in the pathogenesis of T2DM, and the shared cardio-renal complications and other associated morbidities [3].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [3]
In the citing paper
“Obesity and T2D share key pathophysiological mechanisms and are both associated with increased risk for (i) metabolic complications [such as hypertension, dyslipidemia, obstructive sleep apnea (OSA) and metabolic-dysfunction associated steatotic liver disease (MASLD)] and (ii) cardiovascular disease [2,4].”
In the citing paper
“Obesity and T2D share key pathophysiological mechanisms and are both associated with increased risk for (i) metabolic complications [such as hypertension, dyslipidemia, obstructive sleep apnea (OSA) and metabolic-dysfunction associated steatotic liver disease (MASLD)] and (ii) cardiovascular disease [2,4].”
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985 · cited 1×
“Further, renal function sharply declined with increasing age (median [IQR] eGFR; <65 years: 86 [32] ml/min/1.”
BackgroundEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 1×
“BMI: 32 [10] m/kg 2 ) and median BMI declined across the age groups (median [IQR] BMI; <65 years: 34 [10] m/kg 2 , 65-74 years: 32 [9] m/kg 2 , 75+ years: 29 [7] m/kg 2 ).”
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“BMI: 32 [10] m/kg 2 ) and median BMI declined across the age groups (median [IQR] BMI; <65 years: 34 [10] m/kg 2 , 65-74 years: 32 [9] m/kg 2 , 75+ years: 29 [7] m/kg 2 ).”
Prevalence, Expenditures, and Complications of Multiple Chronic Conditions in the Elderly
Wolff, J. L., Starfield, B., & Anderson, G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.20.2269 · Cited by 2,233
Prevalence of Diabetic Retinopathy in the United States, 2005-2008
Zhang, X., Saaddine, J. B., Chou, C.-F., Cotch, M. F., Cheng, Y. J., Geiss, L. S., Gregg, E. W., Albright, A. L., Klein, B. E. K., & Klein, R. (2010) · JAMA · doi:10.1001/jama.2010.1111 · Cited by 1,196
Multimorbidity and quality of life in primary care: a systematic review
Fortin, M., Lapointe, L., Hudon, C., Vanasse, A., Ntetu, A. L., & Maltais, D. (2004) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-2-51 · Cited by 963
Managing patients with multimorbidity in primary care
Wallace, E., Salisbury, C., Guthrie, B., Lewis, C., Fahey, T., & Smith, S. M. (2015) · BMJ · doi:10.1136/bmj.h176 · Cited by 742
The Impact of Comorbid Chronic Conditions on Diabetes Care
Piette, J. D., & Kerr, E. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-2078 · Cited by 731
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010
Stark Casagrande, S., Fradkin, J. E., Saydah, S. H., Rust, K. F., & Cowie, C. C. (2013) · Diabetes Care · doi:10.2337/dc12-2258 · Cited by 719
Time and the Patient–Physician Relationship
Dugdale, D. C., Epstein, R., & Pantilat, S. Z. (1999) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1999.00263.x · Cited by 609
Trends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010
Selvin, E., Parrinello, C. M., Sacks, D. B., & Coresh, J. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2411 · Cited by 532
Gunn, J. M., Ayton, D. R., Densley, K., Pallant, J. F., Chondros, P., Herrman, H. E., & Dowrick, C. F. (2012) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-010-0330-z · Cited by 335
Psychological Distress and Multimorbidity in Primary Care
Fortin, M. (2006) · The Annals of Family Medicine · doi:10.1370/afm.528 · Cited by 300
Comorbidity in patients with diabetes mellitus: impact on medical health care utilization
Struijs, J. N., Baan, C. A., Schellevis, F. G., Westert, G. P., & van den Bos, G. A. (2006) · BMC Health Services Research · doi:10.1186/1472-6963-6-84 · Cited by 277
Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
Monami, M., Genovese, S., & Mannucci, E. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12116 · Cited by 251
Bailey, R. A., Wang, Y., Zhu, V., & Rupnow, M. F. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-415 · Cited by 247
Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits
Ginde, A. A., Blanc, P. G., Lieberman, R. M., & Camargo, C. A. (2008) · BMC Endocrine Disorders · doi:10.1186/1472-6823-8-4 · Cited by 234
Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts
Caughey, G. E., Roughead, E. E., Vitry, A. I., McDermott, R. A., Shakib, S., & Gilbert, A. L. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.019 · Cited by 199
Multimorbidity in primary care: a systematic review of prospective cohort studies
France, E. F., Wyke, S., Gunn, J. M., Mair, F. S., McLean, G., & Mercer, S. W. (2012) · British Journal of General Practice · doi:10.3399/bjgp12x636146 · Cited by 190
The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus
Klein, R., Lee, K. E., Gangnon, R. E., & Klein, B. E. K. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.051 · Cited by 181
Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
Phung, O. J., Schwartzman, E., Allen, R. W., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetic Medicine · doi:10.1111/dme.12232 · Cited by 154
Self-citationManaged care, physician job satisfaction, and the quality of primary care
Grembowski, D. E., Paschane, D. M., Diehr, P. K., Katon, W. J., Martin, D. P., & Patrick, D. L. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.32127.x · Cited by 147
Multiple chronic conditions and healthcare costs among adults
Sambamoorthi, U., Tan, X., & Deb, A. (2015) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.1091730 · Cited by 135
Costs Associated With Multimorbidity Among VA Patients
Yoon, J., Zulman, D., Scott, J. Y., & Maciejewski, M. L. (2014) · Medical Care · doi:10.1097/mlr.0000000000000061 · Cited by 125
Multimorbidity in a cohort of patients with type 2 diabetes
Teljeur, C., Smith, S. M., Paul, G., Kelly, A., & O’Dowd, T. (2013) · European Journal of General Practice · doi:10.3109/13814788.2012.714768 · Cited by 123
Alonso-Morán, E., Orueta, J. F., Esteban, J. I. F., Axpe, J. M. A., González, M. L. M., Polanco, N. T., Loiola, P. E., Gaztambide, S., & Nuño-Solinis, R. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-1059 · Cited by 110
Multiple chronic conditions in type 2 diabetes mellitus: prevalence and consequences.
Lin, P., Kent, D. M., Winn, A. N., Cohen, J. T., & Neumann, P. J. (2015) · PubMed · Cited by 97
Does Diabetes Care Differ by Type of Chronic Comorbidity?
Pentakota, S. R., Rajan, M., Fincke, B. G., Tseng, C., Miller, D. R., Christiansen, C. L., Kerr, E. A., & POGACH, L. M. (2012) · Diabetes Care · doi:10.2337/dc11-1569 · Cited by 79
Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
Brooks, A. D., Salvo, M. C., & Thacker, S. M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s59169 · Cited by 8
Research works printed but not linked: 1
- American Diabetes Association. Standards of medical care in diabetes – 2016. Diabetes Care 2016;39(Suppl 1):S1-S112
Cited by
The Role of Obesity in Type 2 Diabetes Mellitus—An Overview
Chandrasekaran, P., & Weiskirchen, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031882 · Cited by 465
Diabetes, infection risk and COVID-19
Erener, S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101044 · Cited by 351
Nowakowska, M., Zghebi, S. S., Ashcroft, D. M., Buchan, I., Chew-Graham, C., Holt, T., Mallen, C., Van Marwijk, H., Peek, N., Perera-Salazar, R., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1373-y · Cited by 330
Timpel, P., Oswald, S., Schwarz, P. E. H., & Harst, L. (2020) · Journal of Medical Internet Research · doi:10.2196/16791 · Cited by 243
“Hypertension and hyperlipidemia (or hypercholesterolemia) are common comorbidities in patients with type 2 diabetes (T2D), and also show an increasing coprevalence [2,3].”
BackgroundCOVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course
Landstra, C. P., & de Koning, E. J. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649525 · Cited by 206
Metadata
- Authors
- Iglay, K., Hannachi, H., Joseph Howie, P., Xu, J., Li, X., Engel, S. S., Moore, L. M., & Rajpathak, S.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Merck & Co. Inc., Kenilworth, NJ, USA
- Corresponding author
- Iglay, Kristy
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2016-04-04
- Volume
- 32
- Issue
- 7
- Pages
- 1243-1252
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2319839537
- Cited by
- 511
- References
- 32
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 71 · 2023: 81 · 2022: 79 · 2021: 70 · 2020: 50 · 2019: 26 · 2018: 21 · 2017: 20 · 2016: 7
- FWCI
- 23.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, comorbidities, hypertension, overweight and obesity, hyperlipidemia, chronic kidney disease, cardiovascular disease, comorbidity burden, older adults, sex differences, real-world data, electronic health records
- MeSH terms
- Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hyperlipidemias, Hypertension, Male, Middle Aged, Obesity, Retrospective Studies, Comorbidity, Prevalence, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.